Molecular Diagnostic Requisition

COMPLETE ENTIRE FORM AND SUBMIT WITH SPECIMEN TO AVOID DELAYS



665 Stockton Dr. 2001, Exton, PA 19341 P: 610-458-1112 | F: 610-458-1114 | primbioresearch.com

PATIENT LABEL (IF AVAILABLE)					1	. SPECI	MEN COLLEC	PLEASE SUBMIT THE FOLLOWING WITH THE TRF:						
						Collection Date			□ Path	□ Pathological Report □ Insurance Card				
							☐ Credit Card ☐ Patient ID							
2. PATIENT INFORMATION														
Name (Last, First, Middle)					Biological Sex [Date of Birth MRN						
Ethnicity: 🗆 African American 🗆 Asian 🗆 Caucasian 🗆 Hispanic 🗆 Portu						rtuguese 🗆 Other:					Ashke	enazi Jev	lewish: □ Yes □ No	
Address					City				Stat	е	Zip			
Preferred Method of Contact: Phone					E-Mail Preferre				erred Bi	ed Billing:				
□ Phone □ E-mail					□ Insurance* □ Credit Card							dit Card		
*Copy of front/back	of insurance ca	ırd requ	ired. If appl	cable, ple	ase cor	mplete F	Patient Assistan	ce Prog	gram informati	on bel	ow.			
Credit Card Number Exp			Exp(mm/yy)	mm/yy) CVC Cardholder Name and Billing Address (if different)										
3. ORDERING PROVIDER INFORMATION														
Organization Name	ation Name			Address						City, State			Zip)
Ordering Provider Name (Last, First)			Provide	Provider Email			Provider NPI			Phone			Fax	
Genetic Counselor/Other Healthcare Professional Name (Last, First) Phone														
4. PATIENT CLINICAL HISTORY (Attach additional information if necessary)														
Personal History of Cancer Yes No					oe, etc.	cc.)					ICD Code(s)			
Family History of Cancer Family History Details (include relative, cancer type, and age of diagnosis)														
Prior Genetic	Prior Genetic Patient Testing Details Family Members Testing Details													
Testing, IHC, or MSI ☐ Yes ☐ No	Testing, IHC, or MSI													
5. TEST ORDER									<u> </u>					
STEP 1: Select the ind	ication for testin	ng	STEP :	: Select de	esired te					STEP 3: Select Sample Type				
☐ Hereditary/Germline ☐ Somatic ☐ Prin ☐ Prin			☐ PrimBio Cancer Hotspot Panel (6231)				□ FFPE □ Saliva							
			☐ Prin	☐ PrimBio Colorectal Cancer Panel (6232) ☐ PrimBio Breast Cancer Therapy Panel (6233) ☐ PrimBlo MSI Cancer Panel (6234)					□ Blood □ Extracted DNA					
Patient Signature (I agree to the terms below):								<u> </u>		Date:				
Medical Professional Signature (I agree to the terms below):								Date:						
TERMS AND CONDITIONS														
Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to PrimBio Research Institute, LLC (PrimBio), authorize PrimBio to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and have provided herein credit card information. See reverse for limitations of genetic testing. NY residents: I am a New York resident and give PrimBio permission to store my sample for longer than 60 days. NOTE: If left blank, consent is interpreted as "NO".														
Research Use: □ I giv	e consent to Pri	imBio to	de-identify	and use n	ny samp	ole interr	nally for researc	ch purpo	oses. NOTE: If	left blo	ank, coi	nsent is i	interpre	eted as "NO".
Patient Assistance Program: Please provide the total annual gross household income: \$														
Medical Professional: The undersigned person (or representative thereof) ensures he/she is a licensed medical professional authorized to order genetic testing and														

testing is medically necessary and that test results may impact medical management of the patient. Furthermore, all information on this TRF is true to the best of

my knowledge.



665 Stockton Dr. 2001, Exton, PA 19341 | P: 610-458-1112 | F: 610-458-1114 | primbioresearch.com

Supplemental Information

Hereditary Cancer Panels

Test Name	CPT Code	Genes
PrimBio Colorectal Cancer Panel (48 genes)	81435 81436	AKT1, APC, AXIN1, BHD, BLM, BMPR1A, BRAF, BRCA1, BRIP1, BUB1B, CCND1, CDH1, CTNNA1, CTNNB1, DLC1, EIF3E, EP300, EPCAM, FBXW7, FGFR3, GALNT12, GREM1, MCC, MLH1, MLH3, MSH2, MSH6, MUTYH, NRAS, PDGFRL, PIK3CA, PIK3R1, PLA2G2A, PMS1, PMS2, POLD1, POLE, PTEN, PTPRK, RAD51C, RSPO2, RSPO3, SMAD4, STK11, TCF7L2, TGFBR2, TP53, VTI1A
PrimBio Breast Cancer Therapy Panel (69 genes)	81432 81433	AKT1, ATM, BAP1, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CASP8, CCND1, CDA, CDH1, CHEK2, CTLA4, CYB5R1, CYB5R2, CYB5R3, CYB5R4, CYP19A1, DPYD, EGFR, EP300, ERBB2, ERCC1, ESR1, ETV6, F2, F5, FOXA1, G6PD, GATA3, GSTP1, H19, HLA-DQA1, HLA-DRB1, KIT, KRAS, LSP1, MAP2K4, MAP3K1, MRE11A, MSI, MTHFR, MUTYH, NBN, NF1, NRAS, NTRK3, PALB2, PBRM1, PDGFRA, PDGFRB, PIK3CA, PTEN, RAD50, RAD51, RAD51C, RAD51D, RB1, STK11, TERT, TOP2A, TOX3, TP53, TPMT, UGT1A1, XRCC1, XRCC2, XRCC3
PrimBio MSI Cancer Panel	81301 81479	76 Loci associated with MSI

Somatic Cancer Panels

Test Name	CPT Code	Genes
PrimBio Cancer Hotspot Panel (50 genes)	81445 81450	ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, JAK2, JAK3, IDH2, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL
PrimBio Colorectal Cancer Panel (84 genes)	81455	AKT1, ABL1, ALK, APC, ATM, AXIN1, BHD, BLM, BMPR1A, BRAF, BRCA1, BRIP1, BUB1B, CCND1, CDH1, CDKN2A, CSF1R, CTNNA1, CTNNB1, DLC1, EGFR, EIF3E, EP300, EPCAM, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GALNT12, GNA11, GNAQ, GNAS, GREM1, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MCC, MET, MLH1, MLH3, MPL, MSH2, MSH6, MUTYH, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRL, PIK3CA, PIK3R1, PLA2G2A, PMS1, PMS2, POLD1, POLE, PTEN, PTPN11, PTPRK, RAD51C, RB1, RET, RSPO2, RSPO3, SMAD4, SMARCB1, SMO, SRC, STK11, TCF7L2, TGFBR2, TP53, VHL, VTI1A
PrimBio Breast Cancer Therapy Panel (69 genes)	81455	AKT1, ATM, BAP1, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CASP8, CCND1, CDA, CDH1, CHEK2, CTLA4, CYB5R1, CYB5R2, CYB5R3, CYB5R4, CYP19A1, DPYD, EGFR, EP300, ERBB2, ERCC1, ESR1, ETV6, F2, F5, FOXA1, G6PD, GATA3, GSTP1, H19, HLA-DQA1, HLA-DRB1, KIT, KRAS, LSP1, MAP2K4, MAP3K1, MRE11A, MSI, MTHFR, MUTYH, NBN, NF1, NRAS, NTRK3, PALB2, PBRM1, PDGFRA, PDGFRB, PIK3CA, PTEN, RAD50, RAD51, RAD51C, RAD51D, RB1, STK11, TERT, TOP2A, TOX3, TP53, TPMT, UGT1A1, XRCC1, XRCC2, XRCC3
PrimBio MSI Cancer Panel	81301 81479	76 Loci associated with MSI

Limitations & Disclosures

- * Participation in genetic testing is completely voluntary. The patient may withdraw consent or request that their DNA sample be discarded at any time.
- * Current testing may not be able to detect all genetic mutations associated with the suspected condition. The accuracy, implications and limitations of this testing should be reviewed prior to testing.
- * DNA analysis is limited to the requested test and cannot rule out all other genetic conditions or mutations. The correct clinical diagnosis is important for accurate DNA results.
- * DNA testing may reveal information about genes or gene changes other than the requested genetic test. The significance of such a gene change may be unclear. DNA testing may also uncover non-paternity or an undisclosed adoption. Accurate test results depend on knowing the correct relationship between family members.
- * Testing is based on the current level of knowledge in medical genetics. It is the patient and/or physician's responsibility to periodically seek updated information, especially before any reproductive decisions are made. The patient is responsible for keeping their physician(s) informed of address changes and new medical and family history information.
- * Improved or additional testing may become available either because of changes in laboratory techniques or because of new information regarding genetic cause of the condition(s). In some cases, when improved or additional testing becomes available the patient's DNA may be re-tested upon request.
- * Confidentiality will be maintained to the best of our ability as required by the applicable health privacy laws.